6.3% CAGR growth by 2023 in Cervical Cancer Diagnostics and Therapeutics Market |Major Vendors - ABBOTT., ADVAXIS, BECTON, DICKINSON AND COMPANY, BRISTOL-MEYRS SQUIBB COMPANY, F. HOFFMANN-LA ROCHE, GLAXOSMITHKLINE

The global cervical cancer diagnostics and therapeutics market is expected to register a CAGR of 6.3% during the forecast period, 2018 to 2023. North America dominates the market, due to growing prevalence of cervical cancer diseases and rising awareness regarding cervical cancer in the region.

Detailed Sample Copy of Updated Analysis @ https://marketprognosis.com/sample-request/17180

Key Developments in the Market
September 2017 - QIAGEN N.V., launched QIAsure Methylation Test, a novel CE-marked molecular diagnostic test for use in differentiating patient’s risk of developing cervical cancer.

Major Players:
ABBOTT., ADVAXIS, INC., BECTON, DICKINSON AND COMPANY, BRISTOL-MEYRS SQUIBB COMPANY, F. HOFFMANN-LA ROCHE LTD., GLAXOSMITHKLINE PLC, QIAGEN N.V, MERCK & CO., INC., PFIZER INC., QUEST DIAGNOSTICS INC., AMONGST OTHERS.

Favorable Governmental Initiatives toward Cervical Cancer Prevention
The United States assists with coverage and reimbursement on Pap test screening. Federal law has been passed by the Affordable Care Act (ACA) to mandate the coverage of cervical cancer screening tests. It is also supported by self-insured plans. Medicaid, the most popular government insurance program covers screening for cervical cancers. Medicare, another widely used insurance covers Pap test, pelvic exam, and a clinical breast exam for cervical cancer screening every two years for Medicare beneficiaries. There are also support programs like National Breast and Cervical Cancer Early Detection Program (NBCCEDP), which provides cervical cancer screening to women without health insurance for free or at very little cost. According to the Federal Advisory Committee on Immunization Practices (ACIP) recommendations, the US government is trying to include HPV vaccine in the insurance plans and include it as a part of federal Vaccine for Children (VFC) entitlement program. All these governmental initiatives toward cervical cancer prevention have led to the growth of the market.
Additionally, growing prevalence of cervical cancer, increasing awareness regarding early diagnosis, and strong R&D from key players for cervical cancer diagnosis and drugs are anticipated to drive the market of global cervical cancer diagnostics and therapeutics.

Request Discount on this repots @ https://marketprognosis.com/discount-request/17180

Economic Constraints in Many Countries to Adopt Regular Testing Procedures
In middle-income and low-income developing countries, the existing programs are failing to create major impact. This failure is mostly attributed to the lack of or in many cases the absence of a healthcare system that is capable of providing the diagnostic and treatment services inseparable from screening. Many countries of Asia-Pacific and Africa lack a proper healthcare infrastructure to provide the basic medical amenities to people living in rural, and underdeveloped areas. For such remote and hard areas where there is also a social stigma to undergo medical tests, a government or NGO-funded screening program is hard to implement. There is also a definite lack of trained healthcare professionals and a lack of awareness among the people of this region to help achieve an effective implementation of screening programs. Thus, the economic and social constraint in this region will be a major restraint for the major market players trying to invest in this region, which might impede the growth of the global cervical cancer diagnostics and therapeutics market.

Asia-Pacific Expected to Grow Tremendously
Asia-Pacific is expected to grow tremendously during the forecast period, owing to factors, such as high prevalence of cervical cancer. The high prevalence rate of cervical cancer among the population has attributed to factors, such as less awareness regarding sexual hygiene and precaution. High prevalence of cervical cancer, coupled with a greater government emphasis on screening and improvements in diagnosis of cervical cancer are anticipated to boost the market growth in Asia Pacific.

Enquiry Before Buying @ https://marketprognosis.com/enquiry/17180

About Market Prognosis
We at Market Prognosis believe in giving a crystal clear view of market dynamics for achieving success in today’s complex and competitive marketplace through our quantitative & qualitative research methods.
We help our clients identify the best market insights and analysis required for their business thus enabling them to take strategic and intelligent decision.
We believe in delivering actionable insights for your business growth and success.

Contact us:
ProgMark Pvt Ltd,
Thane - 421501
India.
Contact No: +1 973 241 5193
Email: sales@marketprognosis.com

This release was published on openPR.